Cellular Biomedicine Group (CBMG) Downgraded by Zacks Investment Research

Cellular Biomedicine Group (NASDAQ:CBMG) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Wednesday.

According to Zacks, “Cellular Biomedicine Group Inc. is a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases utilizing proprietary cell therapy technologies. The Company offers developmental stem cell, progenitor cell, and immune cell projects. It is developing treatments utilizing proprietary cell technologies for the treatment of a range of cancers; joint disease and central nervous system diseases. Cellular Biomedicine Group Inc. is headquartered in Palo Alto, California. “

Several other equities analysts also recently commented on the company. B. Riley set a $32.00 target price on Cellular Biomedicine Group and gave the stock a “buy” rating in a research report on Monday. BidaskClub downgraded Cellular Biomedicine Group from a “buy” rating to a “hold” rating in a research report on Wednesday, May 9th. ValuEngine upgraded Cellular Biomedicine Group from a “sell” rating to a “hold” rating in a research report on Wednesday, April 4th. Finally, Maxim Group restated a “hold” rating on shares of Cellular Biomedicine Group in a research report on Tuesday, March 6th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $25.00.

Shares of Cellular Biomedicine Group stock traded up $0.10 during midday trading on Wednesday, hitting $17.65. 29,100 shares of the company were exchanged, compared to its average volume of 52,968. The company has a market capitalization of $311.29 million, a PE ratio of -9.92 and a beta of 3.48. Cellular Biomedicine Group has a 52 week low of $5.50 and a 52 week high of $22.75.

Cellular Biomedicine Group (NASDAQ:CBMG) last posted its earnings results on Monday, May 7th. The biotechnology company reported ($0.51) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.05). The company had revenue of $0.05 million for the quarter, compared to the consensus estimate of $0.10 million. Cellular Biomedicine Group had a negative return on equity of 45.67% and a negative net margin of 9,594.83%. sell-side analysts anticipate that Cellular Biomedicine Group will post -1.62 EPS for the current year.

In other Cellular Biomedicine Group news, Director Wen Tao Liu sold 10,400 shares of Cellular Biomedicine Group stock in a transaction on Tuesday, April 10th. The stock was sold at an average price of $20.10, for a total value of $209,040.00. Following the completion of the transaction, the director now owns 223,476 shares in the company, valued at approximately $4,491,867.60. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 8.30% of the company’s stock.

An institutional investor recently bought a new position in Cellular Biomedicine Group stock. Tibra Equities Europe Ltd acquired a new stake in Cellular Biomedicine Group Inc (NASDAQ:CBMG) in the 1st quarter, according to the company in its most recent filing with the SEC. The fund acquired 27,777 shares of the biotechnology company’s stock, valued at approximately $487,000. Tibra Equities Europe Ltd owned about 0.16% of Cellular Biomedicine Group as of its most recent filing with the SEC. 4.09% of the stock is currently owned by institutional investors and hedge funds.

Cellular Biomedicine Group Company Profile

Cellular Biomedicine Group, Inc, a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer, orthopedic, and metabolic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; tumor cell specific dendritic cell therapy; and Re-Join therapy and AlloJoin therapy for the treatment of knee osteoarthritis.

Get a free copy of the Zacks research report on Cellular Biomedicine Group (CBMG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cellular Biomedicine Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit